Skip to main content

Table 2 Standardised AUC for FEV1 at Week 12: treatment comparisons (ITT population)

From: Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study

Treatment Treatment difference
  LSM ± SEM LSM ± SEM
AUC(5 min—4 h) for FEV1   
   Indacaterol 150 μg o.d. 1.54 ± 0.019  
   0.17 ± 0.024*
   Placebo 1.37 ± 0.020  
AUC(5 min—1 h) for FEV1   
   Indacaterol 150 μg o.d. 1.52 ± 0.020  
   0.18 ± 0.024*
   Placebo 1.34 ± 0.020  
AUC(1 h—4 h) for FEV1   
   Indacaterol 150 μg o.d. 1.55 ± 0.020  
   0.17 ± 0.024*
   Placebo 1.37 ± 0.021  
  1. *p < 0.001
  2. AUC = area under the curve; FEV1 = forced expiratory volume in 1 s; ITT = intent-to-treat; LSM = least squares mean; SEM = standard error of mean